Company intelligence / Profile preview

MetasTx

Basking Ridge, New Jersey, United Statesmetastx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

MetasTx has successfully concluded studies showing the role of PAK1 in epithelial-to-mesenchymal transition (EMT). Their lead compound MTX-101 has demonstrated superior efficacy in inhibiting prostate tumor growth and metastasis in various mouse models of prostate cancer.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

MetasTx next-generation KIT inhibitor

Preclinical

Partnerships

J-STAR Research, Inc.

Beyond the preview

Go deeper on MetasTx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MetasTx.

Explore the full profile